|Expert Review of the Autoimmune Model and the Design of Immudel-gp120|
The Institute for Applied Biomedicine actively seeks the opinions of scientific experts throughout all stages of drug development. We welcome careful review by any expert.
The autoimmune model of AIDS and the design of Immudel-gp120 have been examined by professors, researchers, and clinicians in a variety of fields including biology, chemistry, biochemistry, immunology, virology, and AIDS. None of these experts have ever offered a single scientific objection to either the autoimmune model or the design of Immudel-gp120. They have presented no reasons why the model is flawed or why Immudel-gp120 would fail.
The Institute detailed the model and drug design in a major scientific article and submitted it to the peer-reviewed journal, Medical Hypotheses. The article was accepted very promptly and with no changes, despite being twice the journal's usual maximum length. The editor, Dr. David Horrobin, wrote in his acceptance letter, "This is a very interesting and stimulating paper and I hope it will have substantial impact." (See Medical Hypotheses Article)
On September 23, 1998, the Institute's research staff and Board President Frank Andrews met to discuss our project with six AIDS researchers at the National Institute of Allergy and Infectious Diseases in Maryland. This is the branch of the National Institutes of Health that concerns itself with AIDS. All of the participants had read the Medical Hypotheses article, and the Institute gave a brief presentation reviewing key aspects of our work. At that time we did not have the Pilot Test Results.
These people, who are aware of virtually all the AIDS research going on in the world, had no unresolved challenges or criticisms of our project. The meeting was summarized by Dr. Scott Cairns, Program Officer, Division of AIDS, who said, "We agree with you that there may be scientific merit to your hypothesis and encourage you to explore these ideas further." Given that the NIH rarely makes such endorsements, we take this as strong support.
The NIH panel and other experts have raised possible side effects of our drug and asked for clarifications of various points. These issues have been addressed in some detail in the technical sections of this site: Autoimmune Model and Details of Immudel-gp120. If expert opinion or the scientific literature contained evidence that our proposal was flawed, we at the Institute would not be putting our energy into this project. If in the future we receive new scientific review or feedback we will add it, and our reactions, to this website.
© 1997-2008 Institute for Applied Biomedicine. All Rights Reserved. Legal Notices.